Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jun 19, 2021 8:28pm
224 Views
Post# 33417359

RE:RE:RE:RE:RE:What you see now

RE:RE:RE:RE:RE:What you see now
woundedknee wrote: Mugsy..never questioned the science or the pipeline of potential blockbuster drugs this company has in its pipeline. I think it's an amazing investment opportunity. But it seems just when the door starts to open up for a potential share price increase  Dan's poor judgement, imo, stifles that gain. Sometimes, in the heat of the moment my responses may also reflect poor judgement. You and others may disagree with me and that is your right, as long as it leads to healthy debate.
So I would like you to answer this simple question. Do you think that Dan's and Walter's sales had anything to do with this temporary sell down?


Personally, I feel the lack of volume is our biggest problem.
That means ... there's little to no demand except for whoever was buying on the quick run-up in February.
Why aren't investors interest?  Don't know.
Demand dried up.
That won't last forever.

So ... did the share sale have anything to do with the temporary sell-down ?  I highly doublt it.
Did it have some effect? maybe - but temporary if it did.
But ... the question isn't important because we'll never prove it one way or the other.






<< Previous
Bullboard Posts
Next >>